Elation Health Survey: 66% of Primary Care Physicians Report AI Solutions Decrease Administrative Burden Significantly
Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development
bswift Acquires Evive: Launches Integrated Personalized Engagement Platform
World-Class Scientists Gather at Tencent 2024 WE Summit in Chengdu to Share Cutting-Edge Discoveries
CaloPal: The Calorie AI Assistant That Makes Weight Loss Easier
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its...
- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved...
NEW HYDE PARK, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- CareMed, a leading independent Specialty Pharmacy, has been selected by...
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in...
Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and...
CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its...
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human...
eValuator Quality Module provides real-time risk scoring and quality measurement impactATLANTA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- – Streamline Health...
– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net...
BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery...
Ardena's facilities in Assen (left) and Oss (right) Ardena's facilities in the Netherlands: Assen (left) and Oss (right) GHENT, Belgium,...
BERLIN, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vara, the pioneering AI-enabled early breast cancer detection platform, today announced the successful...
Preliminary Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with approximately $107 million in...
Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were...
BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused...
PALO ALTO, Calif. and NEEDHAM, Mass. and MELBOURNE, Australia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in...
NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin...
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
